NCT01749956View on ClinicalTrials.gov

5-FU, Aflibercept, and Radiation (RT) for Preoperative and Postoperative Patients With Stage II/III Rectal Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

September 30, 2015

Study Completion Date

September 30, 2015

Conditions
Rectal Cancer
Interventions
RADIATION

Radiation

DRUG

Aflibercept

PROCEDURE

Surgery

Abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines

DRUG

FOLFOX6

Trial Locations (11)

23230

Virginia Cancer Institute, Richmond

29210

South Carolina Oncology Associates, Columbia

32503

Woodlands Medical Specialists, Pensacola

32796

Space Coast Cancer Center, Titusville

33705

Florida Cancer Specialists, St. Petersburg

33916

Florida Cancer Specialists, Fort Myers

37203

Tennessee Oncology, PLLC, Nashville

37404

Tennessee Oncology - Chattanooga, Chattanooga

40207

Baptist Hospital East, Louisville

45242

Oncology Hematology Care, Inc., Cincinnati

71304

Oklahoma University, Oklahoma City

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

Sanofi

INDUSTRY

lead

SCRI Development Innovations, LLC

OTHER